Sumatriptan

What it is

Sumatriptan was the first triptan. It is a prescription drug used to stop a migraine attack once it has started, and it comes as tablets, injection, nasal spray and suppository. The injection is also approved for cluster headache.

What the research says

Large Cochrane reviews show it works for acute migraine. With a 50 mg tablet, about 28% of people are pain-free at two hours versus 11% on placebo. With a 6 mg injection, the figure is about 59% versus 15%. It does not prevent migraines. Side effects are common but usually brief, such as tingling, warmth, and tightness in the chest or throat. Rare heart attacks and strokes have been reported, so it is not used in people with heart disease. Using it often can cause medication-overuse headache.

Evidence grade: Well established.

How it works

Drug class: Serotonin 5-HT1B/1D receptor agonist (triptan)

Sumatriptan activates serotonin 5-HT1B/1D receptors on blood vessels in the head and on the trigeminal pain nerves. This narrows the widened vessels and blocks the release of inflammatory peptides. (Source 1)

What it is used for

• Across 52,236 participants, every licensed route beat placebo. The 6 mg injection worked best (NNT 2.3 for pain-free at 2 h), and the 50 mg tablet had an NNT of 6.1. Evidence: established. (Source 2)
• In a small Cochrane review, 48% were pain-free within 15 minutes of a 6 mg injection versus 17% on placebo. The tablet label says safety and effectiveness for cluster headache have not been established, and reviewers say oral routes are not appropriate. Evidence: limited. (Source 3)
• The label states sumatriptan is not indicated for preventing migraine attacks. We found no trial evidence reviewed here that supports that use. Evidence: not-supported. (Source 4)
• The tablet label says five adolescent trials of the tablets and two of the nasal spray did not establish efficacy over placebo. A 2026 network meta-analysis found sumatriptan nasal spray, and sumatriptan with naproxen, beat placebo for pain freedom at 2 hours. Evidence: disputed. (Source 5)

Interactions

• MAO-A inhibitor drugs (e.g. some antidepressants) (label): These drugs block the enzyme that breaks down sumatriptan, raising exposure about seven-fold. The label contraindicates using them together. (Source 6)
• SSRI and SNRI antidepressants (label): The label warns of serotonin syndrome. A 14-year cohort found definite cases were rare (0.6 per 10,000 person-years), and its authors questioned the 2006 FDA advisory. (Source 6)
• Other triptans and ergot drugs (label): Their blood-vessel-narrowing effects may add up. The label contraindicates taking another triptan within 24 hours. (Source 6)

Stopping it

• Sumatriptan causes no dependence syndrome, but overuse can cause medication-overuse headache. The label says treatment may need withdrawal of the overused drug, and headache often gets briefly worse during withdrawal. (Source 7)
• A German guideline reports that a stepped approach (education, then preventive treatment, then pausing acute medication) succeeds in 50-70% of people after 6-12 months. (Source 8)

What goes wrong

Adverse events were more common on oral sumatriptan than placebo and rose with dose, though they were mostly brief and mild. (Source 9)

• Systematic review, Certainty not rated.
• Size: 61 studies, 37,250 participants.
• Who: Adults with migraine.
• How long: Single attack.
• Result: Clear dose-response 25-100 mg.
• Funding: not stated in abstract.

For the most part, adverse events were transient and mild and were more common with the sumatriptan than with placebo, with a clear dose response relationship (25 mg to 100 mg).

The label lists the most common side effects in placebo-controlled trials of the tablets (seen in at least 2% of patients and more often than on placebo): tingling or pins and needles, warm or cold sensations, chest pain, tightness, pressure or heaviness, neck, throat or jaw pain or pressure, other pain or pressure sensations, vertigo, and tiredness. (Source 10)

• Official position, Certainty not rated.
• Size: Placebo-controlled registration trials of IMITREX tablets.
• Who: Adults with migraine in registration trials.
• How long: Single attack.
• Result: Each listed reaction occurred in at least 2% of patients and more often than with placebo.
• Funding: industry-funded (GSK registration trials)

Most common adverse reactions (≥2% and >placebo) were paresthesia, warm/cold sensation, chest pain/tightness/pressure and/or heaviness, neck/throat/jaw pain/tightness/pressure, other sensations of pain/pressure/tightness/heaviness, vertigo, and malaise/fatigue.

The label reports rare serious cardiac reactions, including heart attack within hours of a dose, some in people without known heart disease. (Source 11)

• Official position, Certainty not rated.
• Size: Postmarketing reports.
• Who: Patients using sumatriptan.
• How long: Hours after dosing.
• Result: Rare; frequency not quantified.
• Funding: not applicable.

There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of IMITREX tablets.

Serotonin syndrome was rare in people co-prescribed a triptan and an SSRI or SNRI antidepressant: 2 definite cases in 30,928 person-years. (Source 12)

• Cohort study, Low certainty.
• Size: 19,017 co-prescribed patients; 30,928 person-years.
• Who: Patients in the Greater Boston area, 2001-2014.
• How long: 14 years.
• Result: Definite serotonin syndrome 0.6 per 10,000 person-years (95% CI 0.0-1.5); definite plus possible 2.3 per 10,000.
• Funding: not stated in abstract.

Only 2 patients were classified as having definite serotonin syndrome (incidence rate, 0.6 cases per 10 000 person-years of exposure; 95% CI, 0.0-1.5).

Using triptans on 10 or more days a month can worsen headache (medication-overuse headache). (Source 7)

• Official position, Certainty not rated.
• Size: Not stated.
• Who: People using acute migraine drugs.
• How long: Ongoing use.
• Result: Threshold 10 or more days per month.
• Funding: not applicable.

Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache).

What the evidence supports

Oral sumatriptan 50 mg relieved migraine better than placebo, with an NNT of 6.1 for being pain-free at two hours. (Source 9)

• Systematic review, Certainty not rated.
• Size: 61 studies, 37,250 participants.
• Who: Adults with migraine attacks.
• How long: Single attack, 2-24 hours.
• Result: Sumatriptan 50 mg NNTs: 6.1 pain-free 2 h; 7.5 headache relief 1 h; 4.0 headache relief 2 h.
• Funding: not stated in abstract; many trials were manufacturer-run.

For sumatriptan 50 mg versus placebo the NNTs were 6.1, 7.5, and 4.0 for pain-free at two hours and headache relief at one and two hours, respectively.

Across routes, the 50 mg tablet made about 28% pain-free at two hours versus 11% on placebo. The 6 mg injection made about 59% pain-free versus 15%. (Source 2)

• Review of reviews, Certainty not rated.
• Size: Four Cochrane reviews, 52,236 participants.
• Who: Adults with moderate or severe migraine.
• How long: Single attack.
• Result: Injection 6 mg: 59% vs 15%, NNT 2.3 (2.1 to 2.4); oral 50 mg: 28% vs 11%, NNT 6.1 (5.5 to 6.9)
• Funding: not stated in abstract.

the oral 50 mg dose providing complete relief of pain in almost 3 in 10 people (28%) compared with about 1 in 10 (11%) after placebo (NNT 6.1 (5.5 to 6.9) in 6447 participants)

Subcutaneous sumatriptan 6 mg was the most effective route, with about 6 in 10 people pain-free at two hours. (Source 2)

• Review of reviews, Certainty not rated.
• Size: 2522 participants in this analysis.
• Who: Adults with moderate or severe migraine.
• How long: Single attack.
• Result: 59% vs 15% pain-free at 2 h; NNT 2.3.
• Funding: not stated in abstract.

pain reduced from moderate or severe to none by two hours in almost 6 in 10 people (59%) taking 6 mg sumatriptan, compared with approximately 1 in 7 (15%) taking placebo

For cluster headache, a 6 mg injection made 48% of people pain-free within 15 minutes, against 17% on placebo. (Source 3)

• Systematic review, Low certainty.
• Size: 6 studies; 131 given sumatriptan 6 mg, 326 placebo overall.
• Who: Adults with episodic or chronic cluster headache.
• How long: Single attack, 15 minutes.
• Result: Pain-free 48% vs 17%, NNT 3.3 (2.4 to 5.0)
• Funding: not stated in abstract.

By 15 minutes after treatment with subcutaneous sumatriptan 6 mg, 48% of participants were pain-free and 75% had no pain or mild pain (17% and 32% respectively with placebo).

A 2026 network meta-analysis in children and adolescents found sumatriptan nasal spray, and sumatriptan with naproxen, beat placebo for pain freedom at 2 hours. (Source 13)

• Meta-analysis, Certainty not rated.
• Size: 30 studies, 8,914 participants, 13 treatments.
• Who: Children and adolescents with migraine.
• How long: Single attack, 2-24 hours.
• Result: Sumatriptan/naproxen OR 2.91 (1.87-4.53) for pain freedom at 2 h; nasal sumatriptan statistically significant.
• Funding: not stated in abstract.

Sumatriptan/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance.

Sumatriptan plus naproxen together made more people pain-free at two hours than placebo, with high-quality evidence. (Source 14)

• Systematic review, High certainty.
• Size: 12 studies with data; 3663 combination, 3682 placebo.
• Who: Adults with migraine.
• How long: Single attack.
• Result: NNT 3.1 (2.9 to 3.5) when pain mild; 4.9 (4.3 to 5.7) when moderate/severe.
• Funding: not stated in abstract.

The NNT for pain-free at two hours was 3.1 (95% confidence interval 2.9 to 3.5) when the baseline pain was mild

What the evidence does not support

A second 6 mg injection after a poor response to the first did not add migraine relief. (Source 15)

• Systematic review, Certainty not rated.
• Size: 35 studies, 9365 participants.
• Who: Adults with migraine.
• How long: Single attack.
• Result: No evidence of added relief from a second dose.
• Funding: not stated in abstract.

There was no evidence of increased migraine relief if a second dose of sumatriptan 6 mg was given after an inadequate response to the first.

A small meta-analysis found no significant link between triptan use and ischaemic events in people with ischaemic risk factors. It rested on only four heterogeneous studies. (Source 16)

• Meta-analysis, Low certainty.
• Size: 4 studies, 426,840 people.
• Who: People with ischaemic risk factors.
• How long: Varied follow-up.
• Result: No significant association reported; pooled ratios not given in the abstract; I2 96.1-98.8% in subgroups.
• Funding: not stated in abstract.

Limit of this finding: The abstract gives confidence intervals and p-values for stroke, heart attack and death but never states the pooled odds or risk ratios, so the size of any effect cannot be read from it, and the intervals should not be treated as effect sizes. The very high heterogeneity (I2 about 97-99%) means the four studies disagreed strongly. The abstract also contains the typo 'f4 studies'; its limitations section confirms four studies were included.

The analysis revealed no significant statistical relationship between triptan use and ischemic events in patients with ischemic risk factors.

Two controlled trials of sumatriptan nasal spray in adolescents did not show it worked better than placebo. These were nasal spray trials, reported in the tablets label. (Source 5)

• Official position, Certainty not rated.
• Size: 1,248 adolescents aged 12-17.
• Who: Adolescents with migraine.
• How long: Single attack.
• Result: Efficacy not established vs placebo.
• Funding: industry (GSK) trials described in the label.

Limit of this finding: This result is for the nasal spray, not the tablets, even though it appears in the tablets label. The same label section separately reports five trials of the tablets in adolescents, which also did not show benefit over placebo.

The trials did not establish the efficacy of IMITREX nasal spray compared with placebo in the treatment of migraine in adolescents.

Five controlled trials of sumatriptan tablets (25 to 100 mg) in adolescents aged 12 to 17 did not show they worked better than placebo. (Source 5)

• Official position, Certainty not rated.
• Size: 701 adolescents aged 12-17 in five trials.
• Who: Adolescents with migraine.
• How long: 2 single-attack and 3 multiple-attack trials.
• Result: Efficacy not established vs placebo.
• Funding: industry (GSK) trials described in the label.

These trials did not establish the efficacy of oral IMITREX compared with placebo in the treatment of migraine in adolescents.

Where the research disagrees

How much the serotonin syndrome warning for triptans with SSRIs/SNRIs matters

• FDA-approved IMITREX label, regulatory position based on case reports: Serotonin syndrome may occur with IMITREX tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors (Source 7)
• Orlova et al., JAMA Neurology 2018, retrospective cohort: Our results cast doubt on the validity of the FDA advisory and suggest that it should be reconsidered. (Source 12)

How much

• Reference intake: Dosing is set by the prescriber. The FDA tablet label, as a position (DailyMed version effective 2025-12-09), lists 25, 50 or 100 mg single doses. (Source 17)
• Upper limit: The tablet label's maximum is 200 mg in a 24-hour period. This is a regulatory position. (Source 17)
• Studied: Oral 25, 50 and 100 mg single doses in the Cochrane oral review. (Source 9)
• Studied: Subcutaneous 4, 6 and 8 mg doses, mostly 6 mg. (Source 15)
• Studied: Subcutaneous 6 mg and 12 mg in cluster headache trials. (Source 3)

A common belief, and what the research shows

The belief: Taking a second injection of sumatriptan helps if the first one did not work.

What the research shows: The Cochrane review found: "There was no evidence of increased migraine relief if a second dose of sumatriptan 6 mg was given after an inadequate response to the first."

Questions and answers

What is it?

Sumatriptan is a synthetic prescription drug from the triptan class, used to stop migraine attacks and, as an injection, cluster headache attacks. (Source 4)

What does it do in the body?

It activates serotonin 5-HT1B/1D receptors on blood vessels in the head and on trigeminal nerves. This narrows the vessels and reduces the release of inflammatory peptides. (Source 1)

Is it good or bad for you?

For stopping a migraine attack it is effective, with side effects that are mostly brief and mild. It carries rare but serious cardiovascular risks and is contraindicated in coronary artery disease. (Source 18)

How do you get more of it?

Does not apply as a nutrient. It is a prescription medicine. The label, as a position, sets the dose options and a daily maximum. (Source 17)

If it is harmful, what reduces it?

It is cleared from the body within hours. If it is being overused, the label says withdrawal of the overused drug may be needed, often with a brief worsening of headache. (Source 7)

Why might someone be low in it or missing it?

Does not apply. Sumatriptan is not a nutrient or body substance. (Source 1)

We searched: DailyMed label and Europe PMC

Which whole foods contain it or feed it?

Does not apply. No food contains sumatriptan. (Source 1)

We searched: DailyMed label and Europe PMC

What happens if you do not have it?

Does not apply. Not taking it causes no deficiency. The label states it is not a preventive drug. (Source 4)

How can you test for it?

No blood test guides sumatriptan use. Before prescribing, the label asks for a cardiovascular evaluation in triptan-naive people who have several cardiovascular risk factors. (Source 11)

References

1. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
2. The Cochrane database of systematic reviews. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.. 2014. PMID 24865446, DOI 10.1002/14651858.cd009108.pub2. Read the source
3. The Cochrane database of systematic reviews. Triptans for acute cluster headache.. 2013. PMID 24353996, DOI 10.1002/14651858.cd008042.pub3. Read the source
4. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
5. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
6. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
7. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
8. Neurological research and practice. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline.. 2022. PMID 36031642, DOI 10.1186/s42466-022-00200-0. Read the source
9. The Cochrane database of systematic reviews. Sumatriptan (oral route of administration) for acute migraine attacks in adults.. 2012. PMID 22336849, DOI 10.1002/14651858.cd008615.pub2. Read the source
10. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
11. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
12. JAMA neurology. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome.. 2018. PMID 29482205, DOI 10.1001/jamaneurol.2017.5144. Read the source
13. Frontiers in pharmacology. Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis.. 2026. PMID 42529232, DOI 10.3389/fphar.2026.1851994. Read the source
14. The Cochrane database of systematic reviews. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults.. 2016. PMID 27096438, DOI 10.1002/14651858.cd008541.pub3. Read the source
15. The Cochrane database of systematic reviews. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults.. 2012. PMID 22336869, DOI 10.1002/14651858.cd009665. Read the source
16. Saudi medical journal. Association between triptan use and ischemic events in patients with ischemic risk factors: A meta-analysis.. 2025. PMID 40516932, DOI 10.15537/smj.2025.46.6.20250106. Read the source
17. US FDA-approved labeling via DailyMed (National Library of Medicine). IMITREX (sumatriptan) tablets prescribing information (GlaxoSmithKline), DailyMed SPL effective 2025-12-09. 2025. Read the source
18. The Cochrane database of systematic reviews. Sumatriptan (oral route of administration) for acute migraine attacks in adults.. 2012. PMID 22336849, DOI 10.1002/14651858.cd008615.pub2. Read the source